Pinsker Bret L, Lin Anthony L, Serfas John D, Spector Zebulon Z, Piccini Jonathan P, Campbell Michael J, Krasuski Richard A
Division of Cardiology, Department of Medicine, Duke University Medical Center, Durham, North Carolina.
Division of Cardiology, Department of Medicine, University of Kansas Health System, Kansas City, Kansas.
Heart Rhythm O2. 2025 Jun 3;6(8):1182-1191. doi: 10.1016/j.hroo.2025.05.028. eCollection 2025 Aug.
The recurrence of arrhythmia following catheter ablation of macro-reentrant atrial tachycardia (MRAT) in repaired tetralogy of Fallot (rTOF) is poorly understood.
To better describe the incidence, mechanisms, and predictors of recurrent atrial arrhythmia following MRAT ablation in rTOF.
Patients with rTOF ≥18 years of age who underwent radiofrequency ablation for MRAT (typical/cavotricuspid isthmus-dependent atrial flutter, incisional/scar-mediated MRAT, upper and lower-loop reentry, or left atrial MRAT) at Duke University Hospital from 1996 to 2023 were identified. The primary outcome examined was the first recurrence of atrial arrhythmia (MRAT, atrial fibrillation, or focal atrial tachycardia) lasting ≥30 seconds, captured on a 12-lead electrocardiogram, ambulatory monitor, or electrophysiologic study. Predictors of outcome were identified using Cox regression and Kaplan-Meier survival analyses.
Among 58 patients who met inclusion criteria, 39 (67.2%) developed the primary outcome over an average follow-up of 5.4 ± 5.5 years. Nine patients (15.5%) underwent repeat (second or third) ablation for recurrence of an index MRAT that was targeted during the initial ablation. Right atrial (RA) area (hazard ratio 1.60 per 10 cm increase, 95% confidence interval 1.15-2.22, < .01) and the presence of atrial fibrillation or focal atrial tachycardia (hazard ratio 3.43, 95% confidence interval 1.25-9.44, = .02) at ablation were predictive of the primary outcome. RA area ≥26.0 cm was associated with decreased arrhythmia-free survival ( = .02).
Following MRAT ablation in rTOF, recurrence of atrial arrhythmia is common and often of distinct mechanism. RA size and the presence of other atrial arrhythmia at ablation may predict recurrence. Extended courses of post-ablation anti-coagulation may prove beneficial in this population.
法洛四联症修复术后(rTOF),大折返性房性心动过速(MRAT)导管消融术后心律失常的复发情况尚不清楚。
更好地描述rTOF患者MRAT消融术后房性心律失常复发的发生率、机制及预测因素。
确定1996年至2023年在杜克大学医院接受MRAT(典型/三尖瓣峡部依赖性房扑、切口/瘢痕介导的MRAT、上下环折返或左房MRAT)射频消融的年龄≥18岁的rTOF患者。主要观察指标为12导联心电图、动态心电图监测或电生理检查记录到的持续≥30秒的房性心律失常(MRAT、房颤或局灶性房性心动过速)首次复发。采用Cox回归和Kaplan-Meier生存分析确定预后的预测因素。
在58例符合纳入标准的患者中,平均随访5.4±5.5年,39例(67.2%)出现主要观察指标。9例(15.5%)因初始消融时靶向的索引MRAT复发而接受重复(第二次或第三次)消融。消融时右房(RA)面积(每增加10 cm,风险比1.60,95%置信区间1.15 - 2.22,P <.01)以及房颤或局灶性房性心动过速的存在(风险比3.43,95%置信区间1.25 - 9.44,P = .02)可预测主要观察指标。RA面积≥26.0 cm与无心律失常生存期缩短相关(P = .02)。
rTOF患者MRAT消融术后,房性心律失常复发常见且机制往往不同。消融时RA大小及其他房性心律失常的存在可能预测复发。延长消融后抗凝疗程可能对该人群有益。